# rhEndostatin Protein Involving Pediatric Patients With Cancer

> **NCT00165373** · PHASE1 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 21 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** rhEndostatin

## Key facts

- **NCT ID:** NCT00165373
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-01
- **Primary completion:** 2005-01
- **Final completion:** 2005-01
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Lack of drug supply
- **Last updated:** 2007-12-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165373, "rhEndostatin Protein Involving Pediatric Patients With Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00165373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*